SMT develops, manufactures and markets minimally invasive cardiovascular devices, including drug-eluting and bare-metal coronary stents, renal stents, PTCA balloon catheters and other cardiac accessories. The company operates a WHO-GMP certified manufacturing plant in Gujarat and maintains two R&D centers, including one in Dublin, Ireland. SMT exports its portfolio to the UK, Spain, Italy, the Netherlands and over 60 other countries, holds CE certification, has multiple process/product patents and has published clinical studies. The company was an early participant in the ‘Make in India’ initiative and claims pioneering achievements such as being the first in the world to receive CE certification for a biodegradable-polymer drug-eluting stent. SMT emphasizes a customer-centric distribution model through a direct sales network and a strong focus on R&D. The company plans to use new capital to finance organic growth, pursue synergistic acquisitions and build an aggressive R&D program to expand its pipeline of next-generation cardiovascular products.

Total raised

$28M

Funding rounds

1

Latest round

Equity

Latest activity

Jan 2024